

1 **Lnc-*ECAL-1* controls cerebrovascular homeostasis by targeting**
2 **endothelium-specific tight junction protein *Cldn5b***

3 Fang-Fang Li, Yu-Lai Liang, Jing-Jing Zhang, Qing Jing

4
5 From Key Laboratory of Stem Cell Biology, Shanghai Jiao Tong University School of Medicine
6 (SJTUSM) & Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences
7 (CAS) (F.-F.L.); CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai
8 Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese
9 Academy of Sciences (CAS) (Y.-L.L., Q.J.); Department of Cardiology, Changhai Hospital (Q.J.);
10 and Affiliated Hospital of Guangdong Medical University (J.-J.Z.).

11
12 **Short title:** Lnc-*ECAL-1* controls cerebrovascular homeostasis

13
14 **Correspondence to:** Qing Jing, Lab of Nucleic Acid & Molecular Medicine, Shanghai Institutes
15 of Nutrition and Health, Chinese Academy of Sciences, Room 2208, New Building of Biological
16 Sciences, 320 Yue-Yang Road, Shanghai 200031, China

17 TEL: 86-21-54920610

18 FAX: 86-21-54920612

19 E-mail: qjing@sibs.ac.cn

20 **The category:** Original article

21 **Word count:** 5589

22 **Summary statement**

23 Long noncoding RNA *ECAL-1* maintains cerebrovascular pattern formation and integrity
24 through regulating the expression of endothelium-specific tight junction protein *Cldn5b*.

25 **Abstract**

26 Cerebrovascular disorder-induced brain blood flow interruption or intracranial hemorrhage pose
27 a great threaten to health. Emerging roles of long-noncoding RNAs (lncRNAs) in diagnosis and
28 treatment of cardiovascular diseases have been recognized. However, whether and how lncRNAs
29 modulate vascular homeostasis, especially network formation remain largely unknown.
30 Here, we identified *ECAL-1*, a long non-coding RNA, as an important determinant for
31 cerebrovascular homeostasis. Using the morpholino- and CRISPR /Cas9-based genetic
32 modifications in combination with *in vivo* confocal imaging in zebrafish, we claimed that
33 inactivation of *ECAL-1* induced the apparent distortion of cerebral vascular pattern accompanied
34 by intracranial hemorrhage. These cerebrovascular abnormalities were associated with decreased
35 proliferation and anomalous interconnection of endothelial cells. Importantly, overexpression of
36 *Cldn5b*, an endothelial cell-specific tight junction protein-encoding gene, could partially rescued
37 the phenotype induced by *ECAL-1* deficiency. Furthermore, bioinformatic analysis and
38 experimental validation revealed that *ECAL-1* sponged miR-23a, which targeted *Cldn5b* 3'UTR
39 and modulated *Cldn5b* expression, to maintain cerebrovascular pattern formation and integrity.
40 Our results presented here revealed that *ECAL-1* specifically controls cerebrovascular network
41 formation and integrity through targeting miR-23a-*Cldn5b* axis. These findings provide a new
42 regulation modality for cerebrovascular patterning and the potential neurovascular disorders, and
43 *ECAL-1*-miR-23a axis represents as an attractive therapeutic target for cerebrovascular diseases.

44

45 **Key Words**

46 LncRNA; cerebrovascular homeostasis; *Cldn5b*; development

47 **Introduction**

48 The homeostasis of brain vascular network is essential for the maintenance of neuronal activities
49 and the relevant physiological functions, and its disorders result in severe pathologies, such as
50 multiple sclerosis, hemorrhagic stroke, epilepsy etc. (Obermeier et al., 2013). Indeed, vascular
51 development undergoes two sequential stages, i.e., vasculogenesis and angiogenesis. Following
52 the formation of vascular network, blood vessels proceed to reshape through selectively fusing
53 and degenerating, and then recruiting peripheral cells, i.e., pericytes, astrocytes, and microglia, to
54 form mature blood vessels (Carmeliet and Jain, 2011; Geudens and Gerhardt, 2011). In the brain,
55 endothelial cells (ECs) are specialized and particularly important in these processes (Dejana et al.,
56 2009; Obermeier et al., 2013), despite both ECs connection and pericytes are involved in the
57 maintenance of vascular integrity (Armulik et al., 2010; Nitta et al., 2003; Wang et al., 2014;
58 Weis and Cheresh, 2005; Xu et al., 2017).

59 Non-coding RNAs emerge as important regulators and effectors in cardiovascular
60 development and diseases (Fish et al., 2008; Wang et al., 2008; Xu et al., 2017; Zhou et al., 2014;
61 Zou et al., 2011). Long non-coding RNAs (lncRNAs) are non-protein coding transcripts longer
62 than 200 nucleotides, and express in a tissue-specific manner (Orom et al., 2010; Rinn and
63 Chang, 2012). They can act as signaling, decoying, guiding or scaffolding molecules to mediate
64 pathophysiological functions (Rinn and Chang, 2012). For instance, *Tie-1 AS* is essential for EC
65 contact junctions by selectively binding to *Tie-1* mRNA (Li et al., 2010). *Braveheart* functions
66 upstream of mesoderm posterior 1 (MesP1) and contributes to cardiovascular lineage
67 commitment (Klattenhoff et al., 2013). *STEEL* modulates angiogenic behavior by forming a
68 complex with poly(ADP-ribose) polymerase 1 (PARP1) (Man et al., 2018). *LincRNA-p21*
69 represents a key regulator of cell proliferation and apoptosis during atherosclerosis (Wu et al.,
70 2014), and sponges miR-130b to promote EC apoptosis and cell cycle progression (He et al.,
71 2015). However, the roles of lncRNAs in organ-specific endothelial function and vascular
72 homeostasis remain unclear.

73 Hundreds of lncRNAs have been identified in zebrafish (Kaushik et al., 2013; Pauli et al.,

74 2012; Ulitsky et al., 2011). Given the great convenience of brain vascular network visualization
75 and genetic manipulation (Chen et al., 2012; Fujita et al., 2011; Vanhollebeke et al., 2015; Xu et
76 al., 2017), herein we adopted zebrafish to elucidate the roles of lncRNAs in cerebrovascular
77 homeostasis and the underlying molecular mechanisms. Here, we identified a lncRNA as
78 endothelial connection associated lncRNA (*ECAL-1*) in zebrafish, and claimed that *ECAL-1* was
79 indispensable for brain EC connection, and determined EC proliferation *in vivo* and central
80 arteries (CtAs) morphogenesis.

81

82 **Results**

83 ***ECAL-1* is required for cerebrovascular homeostasis in zebrafish**

84 To explore the *in vivo* function of *ECAL-1*, we adopted morpholino- and CRISPR/Cas9-mediated
85 gene modifications in zebrafish. The morpholino knockdown was carried out in wild type
86 zebrafish embryos. *ECAL-1* MO was designed to target the splicing site of *ECAL-1*, and
87 micropeptide (MP) MO inhibited the translation of micropeptide (87 amino acids) in *ECAL-1*
88 (Fig.1A). We found that *ECAL-1* MO reduced the expression of *ECAL-1* (Fig. S1D), and MP MO
89 downregulated the expression of GFP bearing a binding site of MP MO (Fig. S1A and S1B). In
90 addition, the expression of *p53* were not changed in embryos injected with *ECAL-1* morpholino
91 (1 pmol) (Fig.S1C), precluding the morpholino-mediated off-target effects that may lead to
92 excessive activation of *p53* (Robu et al., 2007; Rossi et al., 2015). With this approach, we
93 observed that morphology of embryos injected with *ECAL-1* MO and MP MO appeared normal,
94 while ~20% of *ECAL-1* morphants displayed intracranial hemorrhage at 72 hours post
95 fertilization (hpf) (Fig.1C and 1D).

96 Based on the CRISPR/Cas9 system, we generated two knockout lines, i.e., MP mutant
97 without micropeptide translation, and *ECAL-1* mutant without *ECAL-1* expression (Fig.1B and
98 S1E). The expression of *ECAL-1* was reduced to 40% in MP mutants, and we detected barely no
99 expression of *ECAL-1* in *ECAL-1* mutant (Fig.S1E). Approximately 5% of embryos exhibited
100 intracranial hemorrhage, which was no significantly difference among siblings, MP mutants and

101 ECAL-1 mutants (Fig.1C and 1E).

102 Then, to validate the functional phenotype by *ECAL-1* knockdown, we adopted the full
103 length of *ECAL-1* and the coding sequence of micropeptide. Replenishment of *ECAL-1* capped
104 mRNA, rather than the coding sequence of micropeptide, decreased the hemorrhage rate in
105 *ECAL-1* morphants (Fig.1F and 1G), supporting the role of *ECAL-1* in cerebrovascular
106 homeostasis. Experiments with Quantum Dot injection further demonstrated the disruption of
107 cerebral vessels in *ECAL-1* morphants (Fig.1H), highlighting the importance of *ECAL-1* in the
108 development of cerebrovascular network.

109 Collectively, *ECAL-1* is responsible for cerebrovascular integrity to maintain homeostasis
110 during development.

111 ***ECAL-1* determines pattern formation of cerebrovascular network**

112 To further define the vascular abnormalities associated with cerebrovascular homeostasis, we
113 traced the dynamic changes of cerebrovascular network using the transgenic zebrafish
114 *Tg(Kdrl:eGFP)*. The central arteries (CtAs) sprout from PHBC from 32 hpf to 48 hpf (Fujita et
115 al., 2011; Vanhollebeke et al., 2015). Notably, we observed that hemorrhage occurred from 36
116 hpf (Data not shown), and most hemorrhage events occurred from 48 hpf to 60 hpf and appeared
117 more severe from 60 hpf to 72 hpf (Fig.2A). The occurrence of intracranial hemorrhage was
118 coincident with the time window of cerebrovascular network formation, further underscoring the
119 indispensability for *ECAL-1* in cerebrovascular development.

120 In *ECAL-1* morphants and mutants, both the number of CtAs (Fig.S2A, S2B, S2D and S2E)
121 and the penetration depth of CtAs into the hindbrain matter (Fig.S2A, S2C, S2D and S2F) were
122 not affected. However, the pattern of CtAs displayed pruning structures (“H” and “O” type) and
123 anomalous connection in *ECAL-1* morphants and *ECAL-1* mutants (Fig.2B-2E), but not in MP
124 mutants (Fig. 2D and 2E). The morphology of primary vessels in brain (PHBC, MCEV, LDA and
125 CCV) (Fig.S3A-S3D) and trunk (ISV and DLAV) (Fig.S3E and S3F) remained intact in *ECAL-1*
126 morphants. Together, *ECAL-1* modulates the pattern formation of CtAs.

127 ***ECAL-1* is expressed in endothelial cells and neuron of brain**

128 To dissect the action modality of *ECAL-1* in regulating cerebrovascular development, we
129 characterized its expression pattern. Using whole mount *in situ* hybridization, we identified that
130 *ECAL-1* was distributed in blood vessels and parenchyma of brain (Fig.3A c and d). Frozen
131 sections highlighted the expression of *ECAL-1* in vessel wall and the inner part of brain (Fig.3A
132 h and i). *ECAL-1* expression remained at a high level until 120 hpf (Fig.3B). FACS assay
133 confirmed the expression of *ECAL-1* in endothelial cells, while highly in non-endothelial cells
134 (Fig.3C). Fluorescence *in situ* hybridization (FISH) results showed that *ECAL-1* was expressed
135 in some of *flkl*-positive endothelial cells in trunk at 28 hpf, more was expressed in dorsal
136 nervous system (Fig.3D). At 48 hpf, *ECAL-1* was mainly co-localized with neuron marker *HuC*
137 in head (Fig.3E).

138 ***ECAL-1* defect disrupts the connection between endothelial cells**

139 We further asked whether *ECAL-1* modulated the biology of endothelial cells. During this
140 process, migration and proliferation are the main behaviors of vascular endothelial cells.
141 Through measuring the depth of CtAs penetrated into brain matter, we found that *ECAL-1*
142 deficiency didn't affect the migration of ECs (Fig.S2A and S2C). However, the ECs numbers in
143 CtAs was decreased in the *Tg(Flil:negfp,Kdrl:mcherry)* embryos with *ECAL-1* deficiency
144 (Fig.4A and 4B), and those in PHBC was comparable with sibling controls (Fig.4A and 4C). To
145 define the potential role of pericytes in cerebrovascular abnormalities by *ECAL-1* deficiency, we
146 detected the expression of *Pdgfrb*, a pericyte marker. As shown in Fig.4D and 4E, the pericyte
147 coverage of hindbrain CtAs remained unaffected in *ECAL-1* morphants, precluding the
148 contribution of pericytes. Ultra-structure analysis of ECs showed that intercellular junctions were
149 discontinuous. Particularly, intercellular cleft was widened in *ECAL-1* morphants with
150 intracranial hemorrhage (Fig.4F). These results indicated that *ECAL-1* is essential for EC
151 proliferation and intercellular connection in CtAs.

152 ***ECAL-1* controls the expression of endothelial tight junction protein *Cldn5b* to affect 153 cerebrovascular homeostasis**

154 The maintenance of EC connection is predominated by intercellular junctional complexes

155 comprised of tight junction molecules, e.g., adhesion protein Cdh5 and Cldn5 (Dejana et al.,
156 2009; Obermeier et al., 2013). We checked the expression of these tight junction-related
157 molecules, with the results that Cldn5b was reduced, while Cdh5 appeared normal in *ECAL-1*
158 morphants at 30 hpf (Fig.5A). Western blotting examination demonstrated that Cldn5 protein
159 was significantly decreased in *ECAL-1* morphants, and Cdh5 protein was comparable with that in
160 sibling controls at 48 hpf (Fig.5B and 5C). Moreover, immunofluorescent imaging revealed the
161 expression of *Cldn5* in brain vessels, and validated the reduction of Cldn5 proteins by *ECAL-1*
162 deficiency (Fig.5D).

163 CLDN5 plays a vital role in blood brain barrier integrity (Nitta et al., 2003; Wang et al.,
164 2012), and its role in cerebrovascular homeostasis deserves further study. In zebrafish, *Cldn5* has
165 two orthologous genes, *Cldn5a* and *Cldn5b* (Xie et al., 2010). To explore the role of Cldn5 in
166 cerebrovascular homeostasis, we designed MOs targeting the ATG start site of *Cldn5a* or *Cldn5b*,
167 respectively (Fig.S4A). As shown in Fig.S4B-S4E, the level of Cldn5 protein was reduced in
168 *Cldn5a* morphants and *Cldn5b* morphants. About 40% of *Cldn5b* morphants displayed
169 hemorrhage at 72 hpf, while *Cldn5a* morphants exhibited no difference with control embryos
170 (Fig.5E and 5F). Interestingly, *Cldn5b* morphants exhibited more pruning structures than control
171 embryos (Fig.5G).

172 We further observed the status of vasculature in *Cldn5b* morphants. Quantum Dots injection
173 experiment revealed that hemorrhage was obvious in embryos with a lower dosage of *Cldn5b*
174 MO (0.5 pmol), and there was an absence of blood circulation in embryos with a higher dosage
175 of *Cldn5b* MO (1.0 pmol) (Fig.5H). Injection of *Cldn5b* mRNA could partially rescue the
176 hemorrhagic phenotype in *ECAL-1* morphants, while *Cdh5* mRNA could not (Fig.5I). All these
177 results suggested that endothelial tight junction protein Cldn5b functioned downstream of
178 *ECAL-1* to control the cerebrovascular homeostasis, including integrity and pattern formation.

179 ***ECAL-1* May Protect Cldn5b by Acting As a Sponge of miR-23a**

180 It is known that the function of lncRNAs correlates with their localization within cells (Chen,
181 2016; Ulitsky and Bartel, 2013). Using fluorescence *in situ* hybridization and PCR quantification

182 of cytoplasmic and nuclear RNA fractions, we identified that *ECAL-1* was expressed in
183 cytoplasm (Fig.6A and 6B), implicating its non-transcriptional modulation on *Cldn5b* expression.
184 Given the canonical action modality of lncRNAs as molecular sponge (Chen, 2016; He et al.,
185 2015), we further conducted bioinformatic prediction. We found that both *ECAL-1* and *Cldn5b*
186 contained a binding site for miR-23a (Fig.6C), which was also widely expressed in the brain
187 (Fig.6E).

188 To determine whether *Cldn5b* was a target of miR-23a *in vivo*, we co-injected *GFP* mRNAs,
189 which contained wild-type or mutated *Cldn5b* mRNA 3'UTR following GFP coding sequence
190 (CDS), with the mixture containing *dsRed* mRNAs and control or miR-23a mimics at the 1-cell
191 stage. This approach induced a significant downregulation of the expression of GFP bearing a
192 WT 3'UTR, while the expression of GFP bearing a MU 3'UTR was not affected (Fig.6F and 6G),
193 indicating that miR-23a inhibited the translation of *Cldn5b* by targeting *Cldn5b* 3'UTR. Taken
194 together, *ECAL-1* may promoted *Cldn5b* expression by acting as a sponge of miR-23a.

195

196 **Discussion**

197 In this study, we demonstrated that *ECAL-1* was an essential lncRNA component for
198 cerebrovascular integrity in zebrafish. *ECAL-1* determined cerebrovascular pattern formation
199 through modulating CtAs morphology, EC proliferation and connection. Furthermore, we
200 identified the tight junction protein, *Cldn5b*, as a critical target of *ECAL-1*, which may tether
201 miR-23a to achieve the modulation in cytoplasm.

202 Increasing evidences suggest that lncRNAs are of great guiding significance for basic
203 biology (Derrien et al., 2012; Klattenhoff et al., 2013). Our results confirmed the
204 spatial-temporal expression of *ECAL-1* in ECs and neurons. To the best of our knowledge, our
205 work for the first time reported the effects of lncRNA on the maintenance of CtAs morphology
206 and cerebrovascular pattern formation. Loss-of-function experiments revealed the
207 indispensability of *ECAL-1* in brain angiogenesis, and its deficiency caused irregularity of
208 cerebrovascular pattern and EC connection. Of note, despite the difference of intracranial

209 hemorrhage rate in morphants, MP mutants and ECAL-1 mutants, it was consistent that defect of
210 *ECAL-1*, rather than its encoded micropeptide, caused aberrant CtAs and EC connection.
211 Potential reasons may underlie the hemorrhagic discrepancy, and the most likely possibility is
212 that genetic compensation resulted in differential phenotype between morphants and Cas9
213 mutants. Rescue analysis by *ECAL-1* mRNA and micropeptide coding sequence in *ECAL-1*
214 morphants confirmed that hemorrhage were owing to *ECAL-1* absence, and not relevant to any
215 off-target effects or its encoded micropeptide. The evidence that MP mutants without translation
216 of micropeptide exhibited normal cerebral vasculature and no hemorrhage also supported the
217 conclusion.

218 It is clear that mural cells and junction proteins are pivotal elements for vascular integrity
219 (Dejana et al., 2009; Obermeier et al., 2013; Spadoni et al., 2017). In the present study, no
220 defects of pericyte coverage in *ECAL-1* morphants were observed, whereas ultra-structure
221 analysis revealed the aberrant connection between endothelial cells in *ECAL-1* morphants. These
222 findings precluded the contribution of pericyte coverage in *ECAL-1*-defect-induced
223 cerebrovascular disorders.

224 The core roles of tight junction protein Claudin5 (CLDN5) in blood-brain barrier
225 permeability of mammals have been identified (Nitta et al., 2003) (He et al., 2015). In zebrafish,
226 *Cldn5a* expanded the expression in brain vessels from 72 hpf (van Leeuwen et al., 2018), while
227 *Cldn5b* is enriched in brain vasculature at 48 hpf (Xie et al., 2010). *Cldn5a* is involved in brain
228 ventricular development (Zhang et al., 2010), and the function of *Cldn5b* remains unknown. Our
229 work with loss-of-function and rescue experiments revealed that *Cldn5b* dominated the
230 development of cerebrovascular pattern, and controlled vascular integrity. Interestingly, we
231 noticed that the degree of bleeding was more severe in *Cldn5b* morphants than in *ECAL-1*
232 morphants. This inconsistency probably results from that *ECAL-1* is not the only upstream
233 regulator.

234 The functions of lncRNAs are not only related to its subcellular localization (Chen, 2016;
235 Ulitsky and Bartel, 2013), but also involved in the flank genes. Our data indicated that *ECAL-1*

236 may act as a sponge of miR-23a to regulate the translation of *Cldn5b* in the cytoplasm, and it did
237 not regulate flanking genes expression *in cis* (Fig. S5). Our results further demonstrated that
238 miR-23a inhibited the translation of *Cldn5b*, which was different from the previous report that
239 miR-23a inhibited the EC permeability when its overexpression was conducted in HUVEC and
240 mouse model (Li et al., 2016). This discrepancy maybe attributed to the differential response in
241 different species.

242 It also deserves to note that neurovascular communication also regulates cerebrovascular
243 development, including vascular integrity (Xu et al., 2017). Herein we identified the
244 neuron-enrichment of *ECAL-1* and miR-23a. Thus, we can't preclude the possibility that
245 neuronal *ECAL-1*-miR-23a axis indirectly affected cerebrovascular homeostasis.

246 In summary, our findings reported here provide theoretical basis for underlying mechanism
247 of cerebrovascular homeostasis, and prompt the investigation of lncRNAs in its related diseases.

248

249 **Materials and Methods**

250 **Zebrafish Care and Lines**

251 The Tubingen (TU), *Tg(Kdrl:eGFP)*, *Tg(Fli1:neGFP)^{y7}* and *Tg(Kdrl:HsHRAS-mCherry)^{s896}*
252 zebrafish lines were raised, mated and staged as described previously (Kimmel et al., 1995). Fish
253 maintenance was in accordance with guidelines of the Institutional Review Board of the Institute
254 of Health Sciences, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences
255 (Shanghai, China). All animal experiments have local approval and all animal experiments were
256 carried out in accordance with the National Institutes of Health Guide for the Use of Laboratory
257 Animals and were approved by the Biological Research Ethics Committee of Institute of Health
258 Sciences.

259 **Euthanasia of zebrafish**

260 All animal experiments were performed on zebrafish embryos less than 120 hpf and euthanasia
261 was performed by rapid freezing followed by maceration.

262 **Morpholinos and mRNA Injection**

263 All morpholinos (MOs) were purchased from GeneTools (Philomath, OR) and dissolved in RNA
264 free water (without treatment of DEPC). MOs against *ECAL-1* were designed to block the
265 micropeptide translation initiation or modify the splicing site. A scramble MO was used as a
266 control.

267 Capped mRNA was synthesized with Sp6 (Promega, WI) or T7 RNA polymerase (Roche,
268 Mannheim). Embryos at one-cell stage were injected with 1 nL MO or/and mRNA, and the
269 concentrations were as follows unless specified elsewhere: *ECAL-1* MO, 1 mmol/L; MP MO, 1
270 mmol/L; Control MO, 1 mmol/L; *ECAL-1* mRNA, 200 ng/μL; MP mRNA 200 ng/μL, *dsRed*
271 mRNA, 100 ng/μL.

272 ***In Vitro* Transcription of Cas9 and gRNA**

273 The Cas9 mRNA were synthesized by *in vitro* transcription using T7 RNA polymerase (Roche,
274 Mannheim). The target sites of gRNA starting with “GG” or “GA” were designed manually, and
275 the sequence of a T7 or SP6 promoter was added to the 5’-upstream of gRNA sequence. The
276 Cas9 mRNA and gRNAs were co-injected into 1-cell stage embryos. Each embryo was injected
277 with 1 nL solution containing 200 ng/μL Cas9 mRNA and 100 ng/μL gRNA.

278 The sequence of gRNAs (including T7 promoter and target site) were listed in Table.

279 **Genotype Identification of Mutant Fish Line**

280 Based on the gRNA target site, we design primers to amplify the wild-type or mutated region.
281 We screened the founders by PCR and sequencing. To further confirmation the genotype of
282 *ECAL-1* mutant, we further designed a pair of primers that could only obtain bands in the wild
283 type embryos, not in *ECAL-1* mutants. Primers for genotype identification are shown in
284 supplementary.

285 **O-dianisidine Staining and Scoring of Hemorrhage**

286 TU embryos were collected at 72 hpf, and were stained as previously described (Paffett-Lugassy
287 and Zon, 2005). Embryos with normal gross morphology were enrolled to account the
288 hemorrhage rate, which was divided into four categories, including no hemorrhage, a small
289 hemorrhage site, a large hemorrhage site, and two or more hemorrhage sites.

290 **RNA Extraction and Quantitative Reverse Transcriptase-Polymerase Chain Reaction**
291 **(RT-PCR)**

292 The total RNA from embryos was extracted using TRIzol reagent (Invitrogen) according to the
293 protocol. The total RNA extracted was used to generate cDNA by using Super Script II reverse
294 transcriptase with random primer for mRNA. RT-PCR was performed using SYBR Green
295 (TOYOBO, Japan). The relative RNA amount was calculated with the $\Delta\Delta C_t$ method and
296 normalized with internal control β -actin.

297 **Fluorescent-Activated Cell Sorting (FACS)**

298 To isolate GFP-positive endothelial cells from embryos, about 200 *Tg(Kdrl:eGFP)* embryos at
299 30 hpf were digested into single cell with 1 mL 0.25% trypsin (Gibico, MD) at 28.5 °C until no
300 clumps of tissue are visible to the naked eye. The cells were precipitated by centrifugation (400g,
301 5min) after adding FBS to stop digestion. Then the cell were rinsed with 10% FBS/PBS for three
302 times. After filtration, the cells resuspended solution (10% FBS/PBS) was sorting by (BD SORP
303 FACS Aria).

304 **Isolation of Cytoplasmic and Nuclear RNA Fractions**

305 About 200 *Tg(Kdrl:eGFP)* embryos at 48hpf were digested into single cell in accordance with
306 2.8. Then isolation of cytoplasmic and nuclear RNA fractions was performed as previously
307 described (Chen et al., 2008). Briefly, cells pellets were resuspended in lysis buffer (10mM Tris
308 (pH8.0), 140mM NaCl, 1.5mM MgCl₂, 0.5% Igepal, 2mM vanadyl robonucleoside complex
309 (VRC, Invitrogen, CA), incubated on ice for 5 min. The lysate was centrifuged at 1000g for 3
310 min at 4 °C to pellet the nuclei and the supernatant was the cytoplasmic fraction.

311 **Whole-mount *in situ* Hybridization**

312 Whole-mount *in situ* hybridization with Digoxigenin (Roche, Mannheim) labeled probes was
313 performed in wild type embryos as previously described (Thisse and Thisse, 2008). The
314 sequence of probes for *Kdrl* and *Cmyb* were described previously (Krueger et al., 2011; North et
315 al., 2007). The LNA probe for miR-23a was purchased from Exiqon (Vedbaek, Denmark). The
316 LNA sequence and primers for *in situ* hybridization probes are shown in supplementary.

317 **Fluorescence *in situ* Hybridization and Immunofluorescence**

318 Fluorescence *in situ* hybridization with Digoxigenin (Roche, Mannheim) labeled probe was
319 performed in wild type embryos at the first and second day as previously described (Thisse and
320 Thisse, 2008). The embryos were blocked with 2% Blocking Reagent (Roche, Mannheim) for 1h,
321 and then incubated in a solution of anti-Digoxigenin-POD Fab Fragments (Roche, Mannheim,
322 1:1000). The samples were rocked gently overnight at 4 °C, and washed 6 times for 20 min each
323 with PBST (0.1% Tween in PBS). A buffer containing Cy3 (PerkinElmer, Waltham, 1:50) was
324 used to stain the samples for 40 min.

325 For immunofluorescent imaging, the embryos were incubated with a blocking buffer (PBS
326 with 0.1% tween20, 0.1% TritonX100, 10% goat serum, 1% BSA) for 1h, and then with primary
327 antibody overnight at 4 °C. After washing six times with PBST, embryos were incubated with a
328 secondary antibody (goat anti-mouse IgG, Alexa 488/594; Invitrogen, CA, 1:1000), and imaging
329 ensued.

330 Antibodies used in this study: anti-GFP (Yeasen, China, 1:1000); anti-Claudin5 (Invitrogen,
331 CA, 1:100).

332 **Confocal Imaging and Analysis**

333 Confocal imaging was performed as previously described (Chen et al., 2016; Zou et al., 2011).
334 The embryos were anesthetized in 0.04% Tricaine (Sigma-Aldrich, MO) medium, then were
335 mounted in low melting point Agarose (Sigma-Aldrich, MO). We scanned the interested area
336 with 1.5 µm step size and the format was 1,024x1,024 pixel at 400 Hz. All the confocal images
337 were lateral views, dorsal was up, and anterior to the left unless specifically noted. Both CtAs
338 sprouting in hindbrain and abnormal CtAs were scored in the confocal images.

339 ***In Vivo* Fluorescence Protein Assay**

340 Modified GFP mRNAs bearing *Cldn5b* 3'UTR (wild-type or mutated) following the GFP open
341 reading frame were synthesized by *in vitro* transcription, and they were separately co-injected
342 with miR-23a/control mimic and *dsRed* mRNA into 1-cell stage embryos. The concentrations of
343 the mRNA and mimics were as follows: GFP mRNA, 50 ng/µL; *dsRed* mRNA, 50 ng/µL;

344 miR-23a/control mimic, 2.5 μ M. Fluorescence intensity of GFP and dsRed in trunk were
345 quantified by ImageJ at 30 hpf and dsRed was used as an internal control.

346 **Angiography**

347 Angiography was performed as previously described (Schmitt et al., 2012). Briefly, 55 hpf
348 *Tg(Kdrl:eGFP)* larvae were anesthetized in 0.04% Tricaine (Sigma-Aldrich, MO) medium, and
349 then 2 nl Quantum Dots were injected into venous sinus through a microinjection setup with
350 glass capillaries.

351 **Bioinformatic Analysis**

352 The online tools of genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html and TargetScan
353 were used to identify potential binding sites of miR-23a in *ECAL-1* and *Cldn5b* 3'UTR,
354 respectively.

355 **Statistical Analysis**

356 All the results were generated from at least three independent experiments, and data were
357 presented as means \pm SEM. Statistical analysis was performed using GraphPad. Analysis of
358 differences between two groups was conducted the unpaired Student's two-tailed *t*-test. When
359 more than two groups, statistical differences were performed one-way ANOVA with Tukey's
360 *post-hoc* test. Differences were considered significant when $P < 0.05$. Probability values are
361 indicated by * ($P < 0.05$), ** ($P < 0.01$), or *** ($P < 0.001$).

362

363 **Acknowledgements**

364 We thank Dr. Didier Stainier (Max Planck Institute, Bad Nauheim, Germany) for providing
365 *Tg(Kdrl:HsHRAS-mCherry)^{s896}* transgenic lines; and Dr. Nathan Lawson (University of
366 Massachusetts Medical School, Worcester, USA) for kindly providing the *Tg(Kdrl:eGFP)*. We
367 thank Dr. Jun Li (Shanghai General Hospital, China) for modifying the manuscript; Dr. Jiu-Lin
368 Du (Institute of neuroscience, CAS, Shanghai, China) for kindly providing *Tg(Fli1:neGFP)*; and
369 Dr Jing-Wei Xiong (Peking University, Beijing, China) for providing the plasmids of
370 CRISPR/Cas9 system. We thank all members in Dr. Jing's lab for helpful discussions and

371 comments on this article. We thank Min Deng for technical assistance and Sheng-Rong Yang for
372 zebrafish husbandry.

373

374 **Competing interests**

375 No competing interests declared.

376

377 **Data availability**

378 All relevant data are within the paper and its Supporting Information files

379

380 **Sources of Funding**

381 This work was supported in part by the National Key Research and Development Program of
382 China (2017YFA0103700), the National Natural Science Foundation of China (91339205,
383 91739301, 81130005).

384

385 **References**

386 Armulik, A., Genove, G., Mae, M., Nisancioglu, M.H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P.,
387 Strittmatter, K., et al. (2010). Pericytes regulate the blood-brain barrier. *Nature* *468*, 557-561.

388 <https://doi.org/10.1038/nature09522>

389 Carmeliet, P., and Jain, R.K. (2011). Molecular mechanisms and clinical applications of angiogenesis. *Nature* *473*,
390 298-307. <https://doi.org/10.1038/nature10144>

391 Chen, J., Zhu, R.F., Li, F.F., Liang, Y.L., Wang, C., Qin, Y.W., Huang, S., Zhao, X.X., and Jing, Q. (2016). MicroRNA-126a
392 Directs Lymphangiogenesis Through Interacting With Chemokine and Flt4 Signaling in Zebrafish. *Arteriosclerosis,*
393 *thrombosis, and vascular biology* *36*, 2381-2393. <https://doi.org/10.1161/ATVBAHA.116.308120>

394 Chen, L.L. (2016). Linking Long Noncoding RNA Localization and Function. *Trends in biochemical sciences* *41*,
395 761-772. <https://doi.org/10.1016/j.tibs.2016.07.003>

396 Chen, L.L., DeCerbo, J.N., and Carmichael, G.G. (2008). Alu element-mediated gene silencing. *The EMBO journal* *27*,
397 1694-1705. <https://doi.org/10.1038/emboj.2008.94>

398 Chen, Q., Jiang, L., Li, C., Hu, D., Bu, J.W., Cai, D., and Du, J.L. (2012). Haemodynamics-driven developmental pruning
399 of brain vasculature in zebrafish. *PLoS Biol* *10*, e1001374. <https://doi.org/10.1371/journal.pbio.1001374>

400 Dejana, E., Tournier-Lasserre, E., and Weinstein, B.M. (2009). The control of vascular integrity by endothelial cell
401 junctions: molecular basis and pathological implications. *Developmental cell* *16*, 209-221.

402 <https://doi.org/10.1016/j.devcel.2009.01.004>

403 Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., Guernec, G., Martin, D., Merkel, A., Knowles,

404 D.G., et al. (2012). The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure,
405 evolution, and expression. *Genome research* 22, 1775-1789. <https://doi.org/10.1101/gr.132159.111>
406 Fish, J.E., Santoro, M.M., Morton, S.U., Yu, S., Yeh, R.F., Wythe, J.D., Ivey, K.N., Bruneau, B.G., Stainier, D.Y., and
407 Srivastava, D. (2008). miR-126 regulates angiogenic signaling and vascular integrity. *Developmental cell* 15, 272-284.
408 <https://doi.org/10.1016/j.devcel.2008.07.008>
409 Fujita, M., Cha, Y.R., Pham, V.N., Sakurai, A., Roman, B.L., Gutkind, J.S., and Weinstein, B.M. (2011). Assembly and
410 patterning of the vascular network of the vertebrate hindbrain. *Development* 138, 1705-1715.
411 <https://doi.org/10.1242/dev.058776>
412 Geudens, I., and Gerhardt, H. (2011). Coordinating cell behaviour during blood vessel formation. *Development* 138,
413 4569-4583. <https://doi.org/10.1242/dev.062323>
414 He, C., Ding, J.W., Li, S., Wu, H., Jiang, Y.R., Yang, W., Teng, L., Yang, J., and Yang, J. (2015). The Role of Long
415 Intergenic Noncoding RNA p21 in Vascular Endothelial Cells. *DNA and cell biology* 34, 677-683.
416 <https://doi.org/10.1089/dna.2015.2966>
417 Kaushik, K., Leonard, V.E., Kv, S., Lalwani, M.K., Jalali, S., Patowary, A., Joshi, A., Scaria, V., and Sivasubbu, S. (2013).
418 Dynamic expression of long non-coding RNAs (lncRNAs) in adult zebrafish. *PloS one* 8, e83616.
419 <https://doi.org/10.1371/journal.pone.0083616>
420 Kimmel, C.B., Ballard, W.W., Kimmel, S.R., Ullmann, B., and Schilling, T.F. (1995). Stages of embryonic development
421 of the zebrafish. *Developmental dynamics : an official publication of the American Association of Anatomists* 203,
422 253-310. <https://doi.org/10.1002/aja.1002030302>
423 Klattenhoff, C.A., Scheuermann, J.C., Surface, L.E., Bradley, R.K., Fields, P.A., Steinhauser, M.L., Ding, H., Butty, V.L.,
424 Torrey, L., Haas, S., et al. (2013). Braveheart, a long noncoding RNA required for cardiovascular lineage commitment.
425 *Cell* 152, 570-583. <https://doi.org/10.1016/j.cell.2013.01.003>
426 Krueger, J., Liu, D., Scholz, K., Zimmer, A., Shi, Y., Klein, C., Siekmann, A., Schulte-Merker, S., Cudmore, M., Ahmed,
427 A., et al. (2011). Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish
428 embryo. *Development* 138, 2111-2120. <https://doi.org/10.1242/dev.063933>
429 Li, J., Zhao, Y., Lu, Y., Ritchie, W., Grau, G., Vadas, M.A., and Gamble, J.R. (2016). The Poly-cistronic miR-23-27-24
430 Complexes Target Endothelial Cell Junctions: Differential Functional and Molecular Effects of miR-23a and miR-23b.
431 *Mol Ther Nucleic Acids* 5, e354. <https://doi.org/10.1038/mtna.2016.62>
432 Li, K., Blum, Y., Verma, A., Liu, Z., Pramanik, K., Leigh, N.R., Chun, C.Z., Samant, G.V., Zhao, B., Garraas, M.K., et al.
433 (2010). A noncoding antisense RNA in tie-1 locus regulates tie-1 function in vivo. *Blood* 115, 133-139.
434 <https://doi.org/10.1182/blood-2009-09-242180>
435 Man, H.S.J., Sukumar, A.N., Lam, G.C., Turgeon, P.J., Yan, M.S., Ku, K.H., Dubinsky, M.K., Ho, J.J.D., Wang, J.J., Das, S.,
436 et al. (2018). Angiogenic patterning by STEEL, an endothelial-enriched long noncoding RNA. *Proceedings of the*
437 *National Academy of Sciences of the United States of America* 115, 2401-2406.
438 <https://doi.org/10.1073/pnas.1715182115>
439 Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., Furuse, M., and Tsukita, S. (2003). Size-selective
440 loosening of the blood-brain barrier in claudin-5-deficient mice. *The Journal of cell biology* 161, 653-660.
441 <https://doi.org/10.1083/jcb.200302070>
442 North, T.E., Goessling, W., Walkley, C.R., Lengerke, C., Kopani, K.R., Lord, A.M., Weber, G.J., Bowman, T.V., Jang, I.H.,
443 Grosser, T., et al. (2007). Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. *Nature* 447,
444 1007-1011. <https://doi.org/10.1038/nature05883>

445 Obermeier, B., Daneman, R., and Ransohoff, R.M. (2013). Development, maintenance and disruption of the
446 blood-brain barrier. *Nat Med* 19, 1584-1596. <https://doi.org/10.1038/nm.3407>

447 Orom, U.A., Derrien, T., Beringer, M., Gumireddy, K., Gardini, A., Bussotti, G., Lai, F., Zytynski, M., Notredame, C.,
448 Huang, Q., et al. (2010). Long noncoding RNAs with enhancer-like function in human cells. *Cell* 143, 46-58.
449 <https://doi.org/10.1016/j.cell.2010.09.001>

450 Paffett-Lugassy, N.N., and Zon, L.I. (2005). Analysis of hematopoietic development in the zebrafish. *Methods in*
451 *molecular medicine* 105, 171-198.

452 Pauli, A., Valen, E., Lin, M.F., Garber, M., Vastenhouw, N.L., Levin, J.Z., Fan, L., Sandelin, A., Rinn, J.L., Regev, A., et al.
453 (2012). Systematic identification of long noncoding RNAs expressed during zebrafish embryogenesis. *Genome*
454 *research* 22, 577-591. <https://doi.org/10.1101/gr.133009.111>

455 Rinn, J.L., and Chang, H.Y. (2012). Genome regulation by long noncoding RNAs. *Annual review of biochemistry* 81,
456 145-166. <https://doi.org/10.1146/annurev-biochem-051410-092902>

457 Robu, M.E., Larson, J.D., Nasevicius, A., Beiraghi, S., Brenner, C., Farber, S.A., and Ekker, S.C. (2007). p53 activation
458 by knockdown technologies. *PLoS genetics* 3, e78. <https://doi.org/10.1371/journal.pgen.0030078>

459 Rossi, A., Kontarakis, Z., Gerri, C., Nolte, H., Holper, S., Kruger, M., and Stainier, D.Y. (2015). Genetic compensation
460 induced by deleterious mutations but not gene knockdowns. *Nature* 524, 230-233.
461 <https://doi.org/10.1038/nature14580>

462 Schmitt, C.E., Holland, M.B., and Jin, S.W. (2012). Visualizing vascular networks in zebrafish: an introduction to
463 microangiography. *Methods in molecular biology* 843, 59-67. https://doi.org/10.1007/978-1-61779-523-7_6

464 Spadoni, I., Fornasa, G., and Rescigno, M. (2017). Organ-specific protection mediated by cooperation between
465 vascular and epithelial barriers. *Nature reviews. Immunology* 17, 761-773. <https://doi.org/10.1038/nri.2017.100>

466 Thisse, C., and Thisse, B. (2008). High-resolution in situ hybridization to whole-mount zebrafish embryos. *Nature*
467 *protocols* 3, 59-69. <https://doi.org/10.1038/nprot.2007.514>

468 Ulitsky, I., and Bartel, D.P. (2013). lincRNAs: genomics, evolution, and mechanisms. *Cell* 154, 26-46.
469 <https://doi.org/10.1016/j.cell.2013.06.020>

470 Ulitsky, I., Shkumatava, A., Jan, C.H., Sive, H., and Bartel, D.P. (2011). Conserved function of lincRNAs in vertebrate
471 embryonic development despite rapid sequence evolution. *Cell* 147, 1537-1550.
472 <https://doi.org/10.1016/j.cell.2011.11.055>

473 van Leeuwen, L.M., Evans, R.J., Jim, K.K., Verboom, T., Fang, X., Bojarczuk, A., Malicki, J., Johnston, S.A., and van der
474 Sar, A.M. (2018). A transgenic zebrafish model for the in vivo study of the blood and choroid plexus brain barriers
475 using claudin 5. *Biol Open* 7. <https://doi.org/10.1242/bio.030494>

476 Vanhollebeke, B., Stone, O.A., Bostaille, N., Cho, C., Zhou, Y., Maquet, E., Gauquier, A., Cabochette, P., Fukuhara, S.,
477 Mochizuki, N., et al. (2015). Tip cell-specific requirement for an atypical Gpr124- and Reck-dependent
478 Wnt/beta-catenin pathway during brain angiogenesis. *eLife* 4. <https://doi.org/10.7554/eLife.06489>

479 Wang, S., Aurora, A.B., Johnson, B.A., Qi, X., McAnally, J., Hill, J.A., Richardson, J.A., Bassel-Duby, R., and Olson, E.N.
480 (2008). The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. *Developmental cell*
481 *15*, 261-271. <https://doi.org/10.1016/j.devcel.2008.07.002>

482 Wang, Y., Pan, L., Moens, C.B., and Appel, B. (2014). Notch3 establishes brain vascular integrity by regulating
483 pericyte number. *Development* 141, 307-317. <https://doi.org/10.1242/dev.096107>

484 Wang, Y., Rattner, A., Zhou, Y., Williams, J., Smallwood, P.M., and Nathans, J. (2012). Norrin/Frizzled4 signaling in
485 retinal vascular development and blood brain barrier plasticity. *Cell* 151, 1332-1344.

486 <https://doi.org/10.1016/j.cell.2012.10.042>
487 Weis, S.M., and Cheresh, D.A. (2005). Pathophysiological consequences of VEGF-induced vascular permeability.
488 *Nature* 437, 497-504. <https://doi.org/10.1038/nature03987>
489 Wu, G., Cai, J., Han, Y., Chen, J., Huang, Z.P., Chen, C., Cai, Y., Huang, H., Yang, Y., Liu, Y., et al. (2014). LincRNA-p21
490 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by
491 enhancing p53 activity. *Circulation* 130, 1452-1465. <https://doi.org/10.1161/CIRCULATIONAHA.114.011675>
492 Xie, J., Farage, E., Sugimoto, M., and Anand-Apte, B. (2010). A novel transgenic zebrafish model for blood-brain and
493 blood-retinal barrier development. *BMC Dev Biol* 10, 76. <https://doi.org/10.1186/1471-213X-10-76>
494 Xu, B., Zhang, Y., Du, X.F., Li, J., Zi, H.X., Bu, J.W., Yan, Y., Han, H., and Du, J.L. (2017). Neurons secrete
495 miR-132-containing exosomes to regulate brain vascular integrity. *Cell Res* 27, 882-897.
496 <https://doi.org/10.1038/cr.2017.62>
497 Zhang, J., Piontek, J., Wolburg, H., Piehl, C., Liss, M., Otten, C., Christ, A., Willnow, T.E., Blasig, I.E., and
498 Abdelilah-Seyfried, S. (2010). Establishment of a neuroepithelial barrier by Claudin5a is essential for zebrafish brain
499 ventricular lumen expansion. *Proceedings of the National Academy of Sciences of the United States of America* 107,
500 1425-1430. <https://doi.org/10.1073/pnas.0911996107>
501 Zhou, W., Fong, M.Y., Min, Y., Somlo, G., Liu, L., Palomares, M.R., Yu, Y., Chow, A., O'Connor, S.T., Chin, A.R., et al.
502 (2014). Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. *Cancer cell* 25,
503 501-515. <https://doi.org/10.1016/j.ccr.2014.03.007>
504 Zou, J., Li, W.Q., Li, Q., Li, X.Q., Zhang, J.T., Liu, G.Q., Chen, J., Qiu, X.X., Tian, F.J., Wang, Z.Z., et al. (2011). Two
505 functional microRNA-126s repress a novel target gene p21-activated kinase 1 to regulate vascular integrity in
506 zebrafish. *Circulation research* 108, 201-209. <https://doi.org/10.1161/CIRCRESAHA.110.225045>

507

508 **Figure Legends**

509 **Figure 1. *ECAL-1* was essential for cerebrovascular homeostasis.**

510 (A) Diagram and sequence of morpholinos (MO) target sites. (B) Schematic diagram of
511 *ECAL-1* knockout line and the mutated sequences of micropeptide (MP) mutant and *ECAL-1*
512 mutant. (C) Bright field images of O-dianisidine staining embryos, including morphants and
513 mutants. Hemorrhage sites are indicated by black arrows. (D and E) Statistics of embryos with
514 cranial hemorrhage in *ECAL-1* morphants and mutants. (D) N=304, 303 and 320 for control MO,
515 MP MO and *ECAL-1* MO, respectively. (E) N=387, 501 and 151 for Sibling, MP mutant and
516 *ECAL-1* mutant, respectively. Statistical analysis was conducted using one-way ANOVA *post*
517 *hoc* Tukey test. (F) Statistics of cranial hemorrhage in embryos injected with control MO,
518 *ECAL-1* MO, *ECAL-1* mRNA, micropeptide (MP) mRNA, (*ECAL-1* MO and *ECAL-1* mRNA),
519 (*ECAL-1* MO and MP mRNA). Statistical analysis was conducted using one-way ANOVA *post*

520 *hoc* Tukey test. **(G)** Percentage of cranial hemorrhage in embryos injected with control MO,
521 *ECAL-1* MO, *ECAL-1* mRNA, MP mRNA, (*ECAL-1* MO and *ECAL-1* mRNA), (*ECAL-1* MO
522 and MP mRNA) in different degree. (F and G) N=127, 117, 103, 86, 89 and 99 for control MO,
523 *ECAL-1* MO, *ECAL-1* mRNA, (*ECAL-1* MO + *ECAL-1* mRNA) and (*ECAL-1* MO + MP
524 mRNA), respectively. **(H)** Confocal stack micrographs of head vasculature injected with
525 Quantum Dot at 55hpf, including embryos injected with control embryos, morphants and
526 mutants, respectively. Leakage sites are indicated by white arrows. N=8, 10 and 13 for control
527 MO, *ECAL-1* MO and *ECAL-1* mutant, respectively. Values are means \pm SEM. * $p < 0.05$;
528 *** $p < 0.001$. Scale bar: 200 μ m (C); 100 μ m (H).

529 **Figure 2. *ECAL-1* determines pattern formation of cerebrovascular network.**

530 **(A)** Percentage of cranial hemorrhage in control embryos and *ECAL-1* morphants in different
531 degree at 48hpf, 60hpf and 72hpf. N=353 and 339 for control MO and *ECAL-1* MO, respectively.
532 **(B)** Confocal stack micrographs of embryos injected with control MO and *ECAL-1* MO. Dorsal
533 view of hindbrain at 72hpf. **(C)** Quantification percentage of abnormal hindbrain CtAs of control
534 embryos and *ECAL-1* morphants at 72hpf. N=9 and 9 for control MO and *ECAL-1* MO,
535 respectively. Statistical analysis was conducted using unpaired Student's two-tailed *t*-test. **(D)**
536 Confocal stack micrographs of Sibling, MP mutant and *ECAL-1* mutant. Dorsal view of
537 hindbrain at 72hpf. Statistical analysis was conducted using one-way ANOVA *post hoc* Tukey
538 test. **(E)** Percentage of abnormal CtAs in Sibling, MP mutant and *ECAL-1* mutants at 72hpf. The
539 abnormal CtAs are indicated by red dotted line, and normal CtAs are highlighted by white dotted
540 line. The white arrows indicate the right cerebrovascular patterning. N=13, 11 and 12 for Sibling,
541 MP mutant and *ECAL-1* mutant, respectively. Values are means \pm SEM. *** $p < 0.001$; Scale
542 bar: 50 μ m (B and D).

543 **Figure 3. *ECAL-1* is enriched in endothelial cells and neurons of brain.**

544 **(A)** Expression pattern of *ECAL-1*. (a-g) Whole mount *in situ* hybridization (WISH) in indicated
545 embryos. (h-j) Frozen section for trunk and head. DA: Dorsal aorta, PCV: Posterior cardinal vein,
546 N: notochord. White arrows indicate co-localization of *ECAL-1* and marker genes (*Flk1* or *HuC*).

547 Anterior is to the left except as noted. **(B)** Quantification of *ECAL-1* expression level in different
548 developmental stages by Real-Time PCR. **(C)** Quantification of *ECAL-1* expression level at
549 FACS-sorted vascular endothelial cells (GFP positive) and non-endothelial cells (GFP negative)
550 using Tg(Kdrl:eGFP) transgenic embryos. Each group has about 100 embryos, and this assay
551 was performed three times. Statistical analysis was conducted using unpaired Student's
552 two-tailed *t*-test. **(D)** Double fluorescence *in situ* hybridization (DFISH) for *Flkl1* and *ECAL-1* in
553 trunk and hindbrain. **(E)** Whole-mount and section double fluorescence *in situ* hybridization for
554 *HuC* and *ECAL-1* in hindbrain. The embryos used in Values are means \pm SEM. ****p*<0.001.
555 Scale bar: 100 μ m (a-g in A); 50 μ m (h-j in A); 50 μ m (D and top row in E). 10 μ m (bottom row in
556 E).

557 **Figure 4. Connections between endothelial cells were disturbed in *ECAL-1* deficiency**
558 **embryos.**

559 **(A)** Lateral view of head vasculature in Tg(*Fli1:negfp,Kdrl:mcherry^{Ras}*) embryos injected with
560 control MO and *ECAL-1* MO at 72hpf. **(B and C)** Statistics of endothelial cell number in PHBC
561 (B) and CtAs (C) of control embryos and *ECAL-1* morphants at 72hpf. N=8 and 10 for control
562 MO and *ECAL-1* MO, respectively. Statistical analysis was conducted using unpaired Student's
563 two-tailed *t*-test. **(D)** Fluorescence *in situ* hybridization for *Pdgfrb* and immunofluorescence for
564 GFP in control embryos, *ECAL-1* morphants and *ECAL-1* mutants. **(E)** Statistics of pericytes in
565 hindbrain of control embryos, *ECAL-1* morphants. Statistical analysis was conducted using
566 one-way ANOVA *post hoc* Tukey test. N=8 and 8, for control MO, *ECAL-1* MO, respectively. **(F)**
567 Transmission electron microscopy (TEM) images showing the ultrastructural changes of brain
568 vessels in control embryos and *ECAL-1* morphants. (a and b) The cross section of CtAs. (c and
569 d)The areas outlined by red dashed frame in (a and b). (e and f) Schematic diagram of
570 endothelial cell connection. L:Lumen; EC: Endothelial cell; Values are means \pm SEM.
571 ****p*<0.001. Scale bar: 50 μ m (A); 50 μ m (D); 1 μ m (a and b in F).

572 **Figure 5. *Cldn5b* is a functional downstream effector of *ECAL-1* during cerebrovascular**
573 **homeostasis maintenance.**

574 (A) Detection of *Cldn5b* and *Cdh5* mRNA expression level by whole mount in situ hybridization
575 in control embryos and *ECAL-1* morphants at 30hpf. (B) Detection of *Cldn5* and *Cdh5* protein
576 expression level by Western Blotting at 48hpf. Each group has more than 30 embryos, and this
577 assay was performed three times. (C) Quantitative analysis of three times western blotting results.
578 (D) Immunofluorescence for GFP and *Cldn5* in cross section of control embryos and *ECAL-1*
579 morphants at 72hpf. (E) Bright field images of O-dianisidine staining embryos injected with
580 control MO, *Cldn5a* MO or *Cldn5b* MO at 72 hpf. (F) Statistics of embryos with cranial
581 hemorrhage, including control embryos, *Cldn5a* morphants and *Cldn5b* morphants at 72hpf.
582 N=168, 108 and 153, for control MO, *Cldn5a* MO and *Cldn5b* MO, respectively. Statistical
583 analysis was conducted using one-way ANOVA *post hoc* Tukey test. (G) Confocal stack
584 micrographs of embryos injected with control MO and *Cldn5b* MO (0.5pmol and 1pmol). Dorsal
585 view of hindbrain at 72hpf. The abnormal CtAs are indicated by red dotted line, and normal
586 CtAs are highlighted by white dotted line. The white arrows indicate the right cerebrovascular
587 patterning. (H) Confocal stack micrographs of head vasculature injected with Quantum Dot,
588 including control embryos, *Cldn5b* morphants (0.5 pmol and 1 pmol). (I) Percentage of cranial
589 hemorrhage in embryos injected with control MO, *ECAL-1* MO, (*ECAL-1* MO and *Cdh5*
590 mRNA), or (*ECAL-1* MO and *Cldn5b* mRNA) in different degree. The cranial edema is indicated
591 by asterisk. N=121, 155, 140 and 152, for control MO, *ECAL-1* MO, (*ECAL-1* MO + *Cdh5*
592 mRNA) and (*ECAL-1* MO + *Cldn5b* mRNA), respectively. Values are means \pm SEM. * $p < 0.05$;
593 *** $p < 0.001$. Scale bar: 100 μ m (A); 25 μ m (D); 200 μ m (E); 50 μ m (G); 100 μ m (H).

594 **Figure 6. *ECAL-1* promotes *Cldn5b* by acting as a sponge of miR-23a.**


595 (A) Fluorescence *in situ* hybridization (FISH) for *ECAL-1* and co-localization with DAPI. (B)
596 Quantification of *ECAL-1*, *Actin* and *U6* expression level in nuclear and cytoplasmic fractions of
597 30hpf embryos. Each group has more than 30 embryos, and this experiment was conducted three
598 times. Statistical analysis was conducted using unpaired Student's two-tailed *t*-test. (C) Diagram
599 of miR-23a target sites in *ECAL-1* and *Cldn5b*. (D) Diagram of the 3'UTR of the In vivo reporter
600 assay used. (E) Fluorescence *in situ* hybridization (FISH) for miR-23a and immunofluorescence

601 for GFP in hindbrain. **(F)** In vivo reporter assay of the GFP mRNA bearing wild-type *Cldn5b*
602 3'UTR or mutated 3'UTR co-injected with control mimic, miR-23a mimic at 30 hpf. dsRed
603 mRNA serves as an internal control. **(G)** Quantification of fluorescence density in areas outlined
604 by white dash frame in G. The value of density is calculated by ImageJ. Each group has about 30
605 embryos, and we only observed the embryos with normal gross morphology, and analyzed
606 representative embryos. This assay was performed three times. Statistical analysis was conducted
607 using unpaired Student's two-tailed *t*-test. Values are means \pm SEM. ***p*<0.01; ****p*<0.001.
608 Scale bar: 10 μ m (A); 50 μ m (E); 500 μ m (F).

609 **Figure 7. Functional model of *ECAL-1* in cerebrovascular pattern formation.**

610 Our work revealed that *ECAL-1* regulated *Cldn5b* by acting as a sponge of miR-23a during
611 maintaining cerebrovascular pattern. When knockdown of *ECAL-1*, excessive miR-23a inhibit
612 the translation of tight junction protein *Cldn5b*, resulting in anomalous connection between ECs
613 and abnormal cerebrovascular pattern, even angiorrhhexis and blood cells leaked out of
614 vasculature.


615 **Figures**
616 **Figure 1**



617



618

Figure 2




619

620 **Figure 3**




621

622 **Figure 4**




623

624 **Figure 5**



625

626 **Figure 6**



627

628

629 **Figure7**

